Zacks Investment Research downgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a sell rating in a research report released on Wednesday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other analysts also recently weighed in on ANAB. Stifel Nicolaus set a $127.00 target price on AnaptysBio and gave the stock a buy rating in a research report on Sunday, November 11th. SunTrust Banks dropped their target price on AnaptysBio to $125.00 and set a buy rating for the company in a research report on Friday, January 18th. Credit Suisse Group set a $143.00 target price on AnaptysBio and gave the stock a buy rating in a research report on Friday, November 9th. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the stock a buy rating in a research report on Friday, November 9th. Finally, ValuEngine downgraded AnaptysBio from a buy rating to a hold rating in a research report on Monday, November 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $125.00.
Shares of NASDAQ ANAB opened at $70.60 on Wednesday. AnaptysBio has a 12 month low of $54.26 and a 12 month high of $133.89.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. As a group, research analysts anticipate that AnaptysBio will post -2.76 earnings per share for the current fiscal year.
In other AnaptysBio news, insider Marco Londei sold 30,048 shares of the business’s stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $66.76, for a total value of $2,006,004.48. Following the completion of the sale, the insider now owns 152,925 shares in the company, valued at $10,209,273. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Hamza Suria sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, January 14th. The shares were sold at an average price of $70.79, for a total value of $2,831,600.00. Following the completion of the sale, the chief executive officer now owns 70,064 shares of the company’s stock, valued at approximately $4,959,830.56. The disclosure for this sale can be found here. Insiders sold a total of 264,023 shares of company stock valued at $18,598,848 in the last 90 days. 20.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Quantamental Technologies LLC bought a new stake in AnaptysBio in the fourth quarter valued at approximately $38,000. Diag Capital Management LP bought a new stake in AnaptysBio in the fourth quarter valued at approximately $95,000. SG Americas Securities LLC bought a new stake in AnaptysBio in the fourth quarter valued at approximately $126,000. Rockefeller Capital Management L.P. bought a new stake in AnaptysBio in the third quarter valued at approximately $203,000. Finally, Smith Asset Management Group LP bought a new stake in AnaptysBio in the fourth quarter valued at approximately $149,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Recommended Story: Are all No-Load Funds Equal?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.